CS
EXAS

Candriam SCA’s Exact Sciences EXAS Stock Holding History

Candriam SCA’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-166,157
Closed -$16.9M – 708
2025
Q4 		$16.9M Sell
166,157
-179,242
-52% -$14.4M 0.08% 208
2025
Q3 		$18.9M Hold
345,399
– – 0.1% 189
2025
Q2 		$18.4M Sell
345,399
-11,576
-3% -$588K 0.11% 181
2025
Q1 		$15.5M Sell
356,975
-4,688
-1% -$237K 0.1% 189
2024
Q4 		$20.3M Sell
361,663
-94,928
-21% -$5.91M 0.12% 165
2024
Q3 		$31.1M Buy
456,591
+244,064
+115% +$13.8M 0.18% 122
2024
Q2 		$8.98M Buy
212,527
+15,774
+8% +$868K 0.05% 269
2024
Q1 		$13.6M Sell
196,753
-81,917
-29% -$5.18M 0.09% 219
2023
Q4 		$20.6M Buy
278,670
+131,582
+89% +$8.62M 0.14% 156
2023
Q3 		$10M Buy
147,088
+137,169
+1,383% +$11.6M 0.07% 230
2023
Q2 		$931K Sell
9,919
-7,267
-42% -$567K 0.01% 609
2023
Q1 		$1.07M Buy
17,186
+5,251
+44% +$338K 0.01% 691
2022
Q4 		$591K Sell
11,935
-114,324
-91% -$4.67M ﹤0.01% 791
2022
Q3 		$4.1M Buy
126,259
+118,424
+1,511% +$4.88M 0.03% 424
2022
Q2 		$309K Sell
7,835
-4,423
-36% -$237K ﹤0.01% 758
2022
Q1 		$857K Sell
12,258
-224,575
-95% -$16.4M 0.01% 681
2021
Q4 		$18.4M Buy
236,833
+5,974
+3% +$527K 0.12% 187
2021
Q3 		$22M Sell
230,859
-8,133
-3% -$859K 0.15% 159
2021
Q2 		$29.7M Buy
238,992
+63,118
+36% +$7.53M 0.2% 117
2021
Q1 		$22.4M Sell
175,874
-2
-0% -$274 0.19% 136
2020
Q4 		$23.3M Sell
175,876
-66,704
-27% -$8.07M 0.18% 137
2020
Q3 		$24.7M Buy
242,580
+54,652
+29% +$4.72M 0.23% 103
2020
Q2 		$16.3M Buy
187,928
+71,571
+62% +$5.72M 0.17% 147
2020
Q1 		$10.5M Buy
116,357
+25
+0% +$2.03K 0.12% 204
2019
Q4 		$10.8M Buy
116,332
+61,690
+113% +$5.42M 0.12% 206
2019
Q3 		$4.94M Buy
54,642
+20,183
+59% +$2.3M 0.07% 324
2019
Q2 		$4.05M Buy
34,459
+10,700
+45% +$1.08M 0.05% 378
2019
Q1 		$2.06M Buy
23,759
+18,994
+399% +$1.62M 0.03% 491
2018
Q4 		$301K Buy
+4,765
New +$327K ﹤0.01% 744

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Candriam SCA's EXAS Position: Q1 2026 in Review

Candriam SCA sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 166,157 shares — an estimated $16.9M sold.

Candriam SCA first reported a position in EXAS in Q4 2018 and held it in 29 quarters. The position peaked at $31.1M in Q3 2024. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Candriam SCA reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Candriam SCA sold 166,157 Exact Sciences shares in Q1 2026, an estimated $16.9M.
  • Candriam SCA first reported a position in Exact Sciences in Q4 2018 and held it in 29 quarters.
  • Candriam SCA's Exact Sciences position peaked at $31.1M in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.